Editor
Medical Technology Stock Letter
John McCamant was named editor of the Medical Technology Stock Letter in August 2000. He has spent 35 years on the front lines of biotechnology investing as an equities analyst and in venture capital. His expertise in biotechnology investments is a subject of media interest, and he is frequently consulted and quoted by The Washington Post, BusinessWeek, Reuters, and Bloomberg.
Vaxart (VXRT) is a leader in developing an oral vaccine for COVID-19 that would make it significantl...
Esperion (ESPR) just reported financials ($3 million in net sales) with the stock under pressure as ...
Alkermes (ALKS) announced overwhelming and surprising positive votes from the joint meeting of the P...
Join John McCamant, editor of the Medical Technology Stock Letter, to discover how from vaccines to ...